BR112014031396B1 - composto de sulfamato de fenilalquila e composição de relaxante muscular compreendendo o mesmo - Google Patents

composto de sulfamato de fenilalquila e composição de relaxante muscular compreendendo o mesmo Download PDF

Info

Publication number
BR112014031396B1
BR112014031396B1 BR112014031396A BR112014031396A BR112014031396B1 BR 112014031396 B1 BR112014031396 B1 BR 112014031396B1 BR 112014031396 A BR112014031396 A BR 112014031396A BR 112014031396 A BR112014031396 A BR 112014031396A BR 112014031396 B1 BR112014031396 B1 BR 112014031396B1
Authority
BR
Brazil
Prior art keywords
methyl
preparation example
sulfamate
dioxolan
dioxaspiro
Prior art date
Application number
BR112014031396A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014031396A2 (pt
Inventor
Moon Choi Yong
Original Assignee
Bio Pharm Solutions Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharm Solutions Co Ltd filed Critical Bio Pharm Solutions Co Ltd
Publication of BR112014031396A2 publication Critical patent/BR112014031396A2/pt
Publication of BR112014031396B1 publication Critical patent/BR112014031396B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014031396A 2012-06-15 2013-06-14 composto de sulfamato de fenilalquila e composição de relaxante muscular compreendendo o mesmo BR112014031396B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261660064P 2012-06-15 2012-06-15
PCT/KR2013/005279 WO2013187727A1 (en) 2012-06-15 2013-06-14 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same

Publications (2)

Publication Number Publication Date
BR112014031396A2 BR112014031396A2 (pt) 2017-06-27
BR112014031396B1 true BR112014031396B1 (pt) 2019-11-26

Family

ID=49758484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031396A BR112014031396B1 (pt) 2012-06-15 2013-06-14 composto de sulfamato de fenilalquila e composição de relaxante muscular compreendendo o mesmo

Country Status (9)

Country Link
US (1) US9221783B2 (enExample)
EP (1) EP2861571B1 (enExample)
JP (1) JP6001168B2 (enExample)
KR (1) KR101699145B1 (enExample)
CN (1) CN104428292B (enExample)
BR (1) BR112014031396B1 (enExample)
CA (1) CA2874988C (enExample)
ES (1) ES2635067T3 (enExample)
WO (1) WO2013187727A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088272A1 (en) 2013-12-12 2015-06-18 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating pain
US9937145B2 (en) * 2013-12-12 2018-04-10 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compound for use in preventing or treating epilepsy
ES2704928T3 (es) 2013-12-12 2019-03-20 Bio Pharm Solutions Co Ltd Compuestos derivados de sulfamato para su uso en el tratamiento o alivio del dolor
US11896593B2 (en) * 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459160A (en) * 1891-09-08 Half to isaac l
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US2937119A (en) 1959-06-11 1960-05-17 Carter Prod Inc Nu-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamates
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265727A (en) 1962-06-26 1966-08-09 Armour Pharma Phenyl alkyl-1, 2 dicarbamates
US4591601A (en) 1985-04-12 1986-05-27 Mcneilab, Inc. Anticonvulsant dioxolane methane sulfamates
US4792569A (en) 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5025031A (en) 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
JPH05140144A (ja) * 1991-11-14 1993-06-08 Nitto Denko Corp 新規なアルコール及びその製法、及び新規なエステル並びにこの新規なアルコールからニンジン類の発根誘起物質を製造する方法
JPH07228549A (ja) * 1994-02-17 1995-08-29 Japan Tobacco Inc 新規な4−アリール−2,3−ジヒドロキシ酪酸誘導体及びその製造方法
JP4145492B2 (ja) * 1998-09-23 2008-09-03 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング テトラヒドロピリドエーテル
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
WO2007005935A2 (en) * 2005-07-06 2007-01-11 Molecular Neuroimaging, Llc Norepinephrine transporter radiotracers and methods of syntheses thereof
EP1945651B1 (en) * 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof

Also Published As

Publication number Publication date
EP2861571A1 (en) 2015-04-22
EP2861571A4 (en) 2015-11-04
BR112014031396A2 (pt) 2017-06-27
EP2861571B1 (en) 2017-05-03
CN104428292B (zh) 2017-02-08
CA2874988C (en) 2016-05-24
JP2015531746A (ja) 2015-11-05
CN104428292A (zh) 2015-03-18
JP6001168B2 (ja) 2016-10-05
KR20150023393A (ko) 2015-03-05
US20150266848A1 (en) 2015-09-24
US9221783B2 (en) 2015-12-29
ES2635067T3 (es) 2017-10-02
KR101699145B1 (ko) 2017-02-03
WO2013187727A1 (en) 2013-12-19
CA2874988A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
ES2710902T3 (es) Compuesto derivado de carbamatos de fenilalquilo y composición farmacéutica que contiene el mismo
ES2973331T3 (es) Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo
TW201713649A (zh) 雜環化合物
TW202216705A (zh) 取代哌啶化合物及其用途
ES2886442T3 (es) Profármaco de derivado de aminoácido
ES2626820T3 (es) Moduladores selectivos del receptor de andrógenos
BR112014031396B1 (pt) composto de sulfamato de fenilalquila e composição de relaxante muscular compreendendo o mesmo
JP2015524447A (ja) N−置換ピラゾロ[3,4−d]ピリミジノン類化合物、その製造方法及びその使用
ES2711619T3 (es) Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
ES2704928T3 (es) Compuestos derivados de sulfamato para su uso en el tratamiento o alivio del dolor
ES2967976T3 (es) Compuestos dirigidos a receptor de serotonina
JP6335307B2 (ja) てんかん予防または治療用スルファメート誘導体化合物
TW593330B (en) Orally active A1 adenosine receptor agonists
TW202116780A (zh) Nmda受體調節劑之前驅藥
ES2564366T3 (es) Análogos de encefalina
ES2795418T3 (es) Derivados de difenil purina restringidos periféricamente
CA3191081A1 (en) Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder
JP7209415B2 (ja) ピラゾロピリミジン化合物、医薬組成物、及びその使用
CN119365476A (zh) 一种环戊基腺苷衍生物及其药物用途
TW202241845A (zh) 經取代的環己烷甲醯胺、其製備方法及其治療用途
WO2025033387A1 (ja) 糖脂質誘導体の製造法及びそれらの合成中間体並びにその結晶体

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2013, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2013, OBSERVADAS AS CONDICOES LEGAIS